[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis].
In this article recent advances in research on the pathogenesis of multiple sclerosis (MS) are summarized. New evidence from molecular histopathology is discussed focussing on neurodegenerative aspects. In addition findings with a direct effect on therapeutic decisions are presented which have contributed to improved immunotherapy. During the last decade important advances in immunotherapy have proven especially useful for patients with relapsing-remitting MS. Escalating algorithms are available for both relapses and long-term immunotherapy. Novel therapeutic approaches with monoclonal antibodies have increasing importance, yet side effects are not completely understood. The pathogenetic insights presented here may open new avenues for novel immunotherapies and lead to individualized MS therapy in the future. Limitations are given for primary progressive MS due to the lack of suitable tissue specimens and experimental models. Neuroprotective treatment strategies aiming at the protection of glial and neuronal cells are still in early stages of development.
Gold
R
R
Neurologische Klinik, St. Josef Hospital, Klinikum der Ruhr-Universität, Gudrunstrasse 56, 44791, Bochum, Germany. ralf.gold@ruhr-uni-bochum.de
Rieckmann
P
P
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D000068717:Glatiramer Acetate; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000069442:Natalizumab; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000473:pathology; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009836:Oligodendroglia / Q000187:drug effects / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D018696:Neuroprotective Agents; D010455:Peptides; D011994:Recombinant Proteins; D000074323:Alemtuzumab; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone; D000077561:Daclizumab